This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
by Zacks Equity Research
Investors are likely to focus on Opdivo's demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) posts Q1 results.
Curious about Bristol Myers (BMY) Q1 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Bristol Myers (BMY) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Earnings Preview: Bristol Myers Squibb (BMY) Q1 Earnings Expected to Decline
by Zacks Equity Research
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why
by Zacks Equity Research
The FDA's recent nod to 2seventy bio's (TSVT) Abecma in earlier lines of treatment for relapsed/refractory multiple myeloma is a positive. Also, the R&D asset divestiture to Regeneron is saving costs.
Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed the most recent trading day at $48.51, moving +0.48% from the previous trading session.
Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
by Zacks Equity Research
Roche's (RHHBY) Columvi, in combination with GemOx, achieves the primary endpoint of overall survival in a late-stage lymphoma study.
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
by Zacks Equity Research
Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals are part of the Zacks top Analyst Blog.
ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
by Zacks Equity Research
ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.
Biotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News
by Zacks Equity Research
Moderna (MRNA) and Bristol Myers (BMY) are in focus on pipeline and regulatory updates.
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $51.60, marking a +0.98% move from the previous day.
Bristol Myers (BMY) Reports Positive Colorectal Cancer Study Data
by Zacks Equity Research
Bristol Myers' (BMY) Krazati, in combination with cetuximab, demonstrates clinically meaningful activity as a targeted treatment option for patients with previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer.
Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Abecma
by Zacks Equity Research
Bristol Myers (BMY) wins FDA approval for CAR T cell immunotherapy, Abecma, in earlier lines of treatment for patients with relapsed or refractory multiple myeloma.
FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma
by Zacks Equity Research
Following the label expansion, J&J's (JNJ) Carvykti is approved as a second-line treatment for adults with relapsed/refractory myeloma. It was initially approved for use as a fifth- or later-line treatment.
Merck (MRK) Begins Phase III NSCLC Study on KRAS Candidate
by Zacks Equity Research
Merck's (MRK) phase III study will evaluate KRAS G12C inhibitor candidate MK-1084 for first-line treatment of certain patients with metastatic NSCLC.
Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
by Zacks Equity Research
Disc Medicine, Inc. (IRON) and Verve Therapeutics (VERV) fall on study updates.
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
by Zacks Equity Research
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion
by Zacks Equity Research
Bristol Myers (BMY) receives European Commission's approval for a label expansion of Reblozyl (luspatercept) for another indication.
Bristol Myers Squibb (BMY) Stock Moves -0.47%: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) concluded the recent trading session at $52.74, signifying a -0.47% move from its prior day's close.
Bristol Myers' (BMY) Zeposia Fails Crohn's Disease Study
by Zacks Equity Research
Patients treated with Bristol Myers' (BMY) Zeposia in a phase III study for Crohn's disease did not achieve disease remission.
Bristol Myers Squibb (BMY) Rises Higher Than Market: Key Facts
by Zacks Equity Research
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $53.25, indicating a +1.33% shift from the previous trading day.
Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $51.59, marking a -0.56% move from the previous day.
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
by Zacks Equity Research
Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates.
Bristol Myers (BMY) Gets EC Nod for Abecma's Label Expansion
by Zacks Equity Research
Bristol Myers (BMY) wins European Commission's approval for the label expansion of its CAR T cell immunotherapy Abecma in earlier lines for triple-class exposed relapsed and refractory multiple myeloma.
Fusion (FUSN) Up 99% on $2.4B Buyout Offer From AstraZeneca
by Zacks Equity Research
AstraZeneca (AZN) is set to acquire Fusion Biopharma (FUSN) for $21 per share in cash, along with a contingent value right of $3 per share, tied to a regulatory milestone.